<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7215134\results\search\zoonosis\results.xml">
  <result pre="aligned with those from negative-sense RNA viruses, namely Ebola, Influenza," exact="Rabies" post="and Vesicular Stomatitis viruses [16]. The structure modeling shows"/>
  <result pre="to the one from HCV than the one from negative-sense" exact="Influenza" post="and Ebola RNA viruses. Therefore, repositioning of Sofosbuvir (SovaldiÂ®;"/>
  <result pre="one from HCV than the one from negative-sense Influenza and" exact="Ebola" post="RNA viruses. Therefore, repositioning of Sofosbuvir (SovaldiÂ®; EpclusaÂ® by"/>
  <result pre="NS5B RdRp protein, as antiviral in the treatment of the" exact="SARS-CoV-2 infection" post="has an extremely high potentiality of success, as recently"/>
  <result pre="the molecular structure of the Sofosbuvir and the inhibitors of" exact="Influenza" post="and Ebola viruses currently evaluated in clinical trials (Fig.Â"/>
  <result pre="structure of the Sofosbuvir and the inhibitors of Influenza and" exact="Ebola" post="viruses currently evaluated in clinical trials (Fig.Â 1). Fig."/>
  <result pre="(developed for the influenza virus) and Remdesivir (developed for the" exact="Ebola" post="virus) are shown together with Sofosbuvir (developed for the"/>
  <result pre="lead compound with the highest potential of antiviral efficacy in" exact="SARS-CoV-2 infection." post="In addition, the long-lasting use in patients for treating"/>
 </snippets>
</snippetsTree>
